Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Returning 1504 results

Role of Myeloid Cells in Persistence and Eradication of HIV-1 Reservoirs from the Brain (R01 Clinical Trial Not Allowed)

RFA
Thursday, September 24, 2020
Saturday, January 9, 2021
R01
RFA-MH-20-701

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence in myeloid cells and strategies to target this reservoir in the central nervous system. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Role of Myeloid Cells in Persistence and Eradication of HIV-1 Reservoirs from the Brain (R21 Clinical Trial Not Allowed)

RFA
Thursday, September 24, 2020
Saturday, January 9, 2021
R21
RFA-MH-20-702

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence in myeloid cells and strategies to target this reservoir in the central nervous system. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required. RFA-MH-20-701uses the R01 grant mechanism whileRFA-MH-20-702uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism, while applicants with preliminary data may wish to apply using the R01 mechanism.

Notice of Special Interest: Alzheimers-focused administrative supplements for NIH grants that are not focused on Alzheimers disease

Notice of Special Interest
Wednesday, September 9, 2020
Saturday, October 17, 2020
333
NOT-AG-20-034

Funding Opportunity Purpose

The participating Institutes and Centers (ICs) are inviting applications to expand existing awards that are not currently focused on Alzheimers disease and its related dementias - Frontotemporal dementia, Lewy Body dementia, Vascular Cognitive Impairment with Dementia and multiple etiology dementias - to allow the research to develop such a focus.

NIH Blueprint for Neuroscience Research: Functional Neural Circuits of Interoception (R01, Clinical Trial Not Allowed)

RFA
Wednesday, September 2, 2020
Saturday, December 19, 2020
R01
RFA-AT-21-003

Funding Opportunity Purpose

The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see https://neuroscienceblueprint.nih.gov/). The goal of this FOA is to enhance our fundamental understanding of interoception with a specific focus on dissecting neural circuits connecting peripheral organs/tissues with the central nervous system via peripheral ganglia. For this FOA, interoception science includes studies of the processes by which an organism senses, interprets, integrates, and regulates signals originating from within itself. The FOA encourages projects that combine diverse expertise and use innovative approaches to delineate interoceptive mechanisms at the molecular, cellular, circuitry, functional, and/or behavioral levels. Outcomes of this research will lay a critical foundation for future translational and clinical research on interoception as well as its roles in nervous system disorders. Studies of interoceptive neural circuits exclusively within the central nervous system may consider seeking for BRAIN INITIATIVE funding opportunities.

Center without Walls for Molecular Mechanisms of Neurodegeneration in Frontotemporal Degeneration (FTD) (U54 Clinical Trial not Allowed)

RFA
Monday, August 24, 2020
Tuesday, November 3, 2020
U54
RFA-NS-21-003

Funding Opportunity Purpose

The goal of the Frontotemporal Dementia (FTD) Centers Without Walls (CWOW) is to improve our understanding of the mechanisms underlying neurodegeneration in FTD through multi-disciplinary, team-based science to address a specific challenge or challenges in the field that could not be achieved through individual research projects.

Mechanisms of Selective Vulnerability in LBD and FTD (R01 Clinical Trial Not Allowed)

RFA
Thursday, August 13, 2020
Wednesday, October 28, 2020
R01
RFA-NS-21-007

Funding Opportunity Purpose

Accumulation of abnormal proteins such as alpha-synuclein or tau in the brains of patients with dementia tends to occur in specific brain structures (cells/circuits/regions), resulting in the unique clinical presentations that are characteristic of the different types of dementia. This funding opportunity announcement invites applications that seek to identify mechanisms responsible for this selective regional vulnerability to abnormal protein deposition in the brains of patients with Lewy Body Dementia or Frontotemporal Dementia.

Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional)

RFA
Thursday, August 6, 2020
Wednesday, September 16, 2020
U01
RFA-OD-20-022

Funding Opportunity Purpose

NIH is issuing this RFA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency NOSI from the NIH provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of RADx-rad initiative is to encourage the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, the goal of this RFA is to solicit proposals to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Mechanisms of Pathological Spread of Abnormal Proteins in LBD and FTD (R01 Clinical Trial Not Allowed)

RFA
Thursday, August 6, 2020
Wednesday, October 28, 2020
R01
RFA-NS-21-006

Funding Opportunity Purpose

This funding opportunity announcement invites research on the mechanism(s) by which abnormal proteins spread throughout the nervous systems of patients with Frontotemporal Dementia and/or Lewy Body Dementia. Applications that move beyond a focus on one mechanisms of spread to consider how spreading might proceed in the context of multiple proteinopathies, multiple cell/circuit types, and multiple pathways are of particular interest.

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Chemosensory Testing as a COVID-19 Screening Tool

Notice of Special Interest
Thursday, August 6, 2020
Wednesday, September 16, 2020
333
NOT-OD-20-152

Funding Opportunity Purpose

Notice Special Interest NOSI): Availability Emergency Competitive Revisions Chemosensory Testing a COVID-19 Screening Tool Notice Number: NOT-OD-20-152 Key Dates Release Date: August 6, 2020 First Available Due Date: September 01, 2020 Expiration Date: September 16, 2020 Related Announcements PA-20-135 - Emergency Competitive Revision Existing NIH Awards Emergency Supplement - Clinical Trial Optional) NOT-OD-20-144 - Notice Intent Publish Funding Opportunity Announcements the RADx-rad Initiative RFA-OD-20-022 - Chemosensory Testing a COVID-19 Screening Tool U01 Clinical Trial Optional) RFA-OD-20-019 - Emergency Awards: RADx-rad Data Coordination Center DCC) U24 Clinical Trial Allowed) Issued Office The Director, National Institutes Health OD) National Institute Aging NIA) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) applications this funding opportunity announcement should fall within mission the Institutes/Centers. following NIH Offices co-fund applications assigned those Institutes/Centers. Office Research Women's Health ORWH) Purpose Purpose NIH issuing NOSI response the declared public health emergency issued the Secretary, HHS, 2019 Novel Coronavirus COVID-19). emergency NOSI the National Institutes Health NIH) provides expedited funding mechanism part the Rapid Acceleration Diagnostics-Radical RADx-rad) initiative. goal the RADx-rad initiative to encourage development novel, non-traditional approaches identify current SARS-CoV-2 virus other markers the COVID-19 disease can used future outbreaks COVID-19 that be applicable other, yet unknown, viruses. Specifically, goal this NOSI to solicit proposals enhance utility chemosensory testing a COVID-19 screening tool using objective tests examine onset prognostic value chemosensory loss to encourage development and/or deployment home-based on-site chemosensory tests. funding this initiative provided the Paycheck Protection Program Health Care Enhancement Act, 2020. Background SARS-CoV-2 a novel coronavirus has recently identified the causative agent COVID-19, respiratory disease exhibits wide range clinical outcomes asymptomatic mild disease severe viral pneumonia, Acute Respiratory Distress Syndrome ARDS), Multisystem Inflammatory Syndrome Children MIS-C), acute kidney injury, thrombotic disorders, chemosensory dysfunction, serious cardiac, cerebrovascular vascular complications. March 11, SARS-CoV-2 outbreak classified a pandemic the WHO. Research an important component the public health emergency response before, during after emergency. United States Food Drug Administration FDA)-authorized COVID-19 diagnostic testing critical slowing spread the virus preventing future outbreaks. Given this, is urgent public health need the National Institutes Health NIH) support development a variety approaches testing. Expanding capacity, throughput, regional placement existing technologies accelerating development new technologies contribute significantly the current national efforts curb COVID-19 pandemic. help meet need, NIH launched Rapid Acceleration Diagnostics RADx) initiative speed innovation the development, commercialization, implementation technologies COVID-19 testing. RADx initiative a national call scientists organizations bring innovative ideas new COVID-19 testing approaches strategies. a part this initiative, NIH developed RADx Radical RADx-rad) project. RADx-rad support new, non-traditional approaches, including unconventional screening, biological physiological markers, new platforms, point-of-care devices, address current gaps COVID-19 testing. program also support new non-traditional applications existing approaches enhance usability, accessibility, and/or accuracy. Despite variety activities included, overall RADx-rad effort be centrally aligned coordinated harmonize data collection, storage, management, providing opportunity further explore identify additional approaches understand novel virus. Beyond current crisis, is anticipated the technologies advanced through RADx-rad also applicable other, yet unknown, infectious agents. “Sudden loss smell taste” formally recognized one the hallmarks COVID-19 the CDC has emerged the main neurological manifestation the disease as as 80% patients infected SARS-CoV-2 reporting chemosensory dysfunction. fact, recent observational studies indicate the loss smell taste one the most common symptoms COVID-19 more predictive all symptoms, including fatigue, fever, cough. Most studies date used self-report rather objective chemosensory testing, leading the possibility the prevalence chemosensory loss be even higher among patients COVID-19 previously reported. findings highlight need objective chemosensory tests COVID-19 screening, yield immediate results are validated across lifespan, easy self-administer, quantitative graded allow determination diminished well profound sensory loss. initiative aims support further development, commercialization, implementation technologies chemosensory testing screen patients COVID-19 to complement current temperature screening procedures. Research Objectives NOSI fund competitive revisions existing NIH awards support chemosensory testing a COVID-19 screening tool using objective tests examine onset prognostic value chemosensory loss to encourage development and/or deployment home-based on-site chemosensory tests. Areas interest include: Development deployment standardized validated over counter testing kits tests utilize common household items remote, home-based screening through telemedicine mild moderately affected individuals. Modification existing test platforms e.g. NIH Toolbox®) improve efficiency administration, data collection evaluation using mobile phone apps telemedicine. Development innovative chemosensory platforms can implemented testing large, risk populations, example, health care workers, pregnant women, older adults caretakers residing/working nursing homes long-term care facilities. Establishment appropriate odorants, optimal odorant concentrations, standardized delivery systems protocols the development onsite, group testing stations those working living high-density, high risks environments. Analysis test results determine specificity chemosensory testing respect COVID-19 versus influenza, onset chemosensory dysfunction, the prognostic value chemosensory testing predicting neurological other manifestations. maximize research rapidly implement approaches address COVID-19 pandemic, comparisons across datasets studies data integration essential collaboration. Projects funded through FOA strongly encouraged use following resources applicable: Data Harmonization Social Determinants Health via PhenX Toolkit: Investigators involved human-subject studies strongly encouraged employ common set tools resources will promote collection comparable data social determinants health SDOH) across studies. particular, studies human participants should incorporate SDOH measures the Core Specialty collections are available the Social Determinants Health Collection the PhenX Toolkit www.phenxtoolkit.org). trans-NIH working group making existing COVID-19 survey items investigator contact information publicly available through NIH-supported platforms: NIH Public Health Emergency Disaster Research Response DR2) https://dr2.nlm.nih.gov/] the PhenX Toolkit https://www.phenxtoolkit.org/index.php]. Researchers addressing COVID-19 questions, whether population-based for clinical research, strongly encouraged consider COVID-19 specific survey item repositories select existing survey items protocol modules currently being fielded. Additional Requirements NIH requiring data sharing all COVID-19 projects, where is prohibited i.e., Tribal data sovereignty). NIH expects supports timely release sharing final research data NIH-supported studies use other researchers expedite translation research results knowledge, products, procedures improve human health. Recipients expected work the RADx-rad Data Coordinating Center DCC) submit common evaluation metrics COVID-19 testing-related outcomes implementation the DCC. Recipients should identify dedicated unit responsible these data reporting activities. NIH expects all projects funded under NOSI actively coordinate, collaborate, share data the RADx-rad Data Coordinating Center, allowed, with considerations under tribal IRB processes, appropriate. Researchers applying this funding opportunity strongly encouraged review Data Coordinating Center DCC) funding opportunity. NIH Expects, data acquisition, collection, curation strategies be coordinated the DCC guidance annotation benchmarking data, including obtaining appropriate consent data sharing implementation the schemas proposed under ABOUT ML effort (“Annotation benchmarking understanding transparency machine learning lifecycles”; available https://www.partnershiponai.org/about-ml/). order maximize progress successful outcomes, recipientsare expected participate DCC-organized activities, including regular e.g., monthly) progress meetings individual subsets awardees, twice annual meetings all RADx-rad awardees. Applications must include timeline completion. timeline must include plans regular reports progress be submitted the DCC. Projects must include evaluation plan demonstrating the proposed COVID-19 diagnostic strategies/activities be assessed effectiveness impact. Recipientsare expected obtain retain personal identifiers all research participants where is prohibited i.e., Tribal data sovereignty) future longitudinal follow-up to leveraged intervention research. Data collected this program be protected a Certificate Confidentiality. Recipients must include measures reporting relevant testing implementation outcomes, inform future community, local, state, federal policies. with NIH supported research, details regarding human subjects research expected, including data safety monitoring plans and, needed, plans a Data Safety Monitoring Board DSMB). Studies have DSMB expected coordinate DCC DSMB activities. Recipients expected disaggregate study results sex gender; race ethnicity; age other relevant demographic factors, to consider intersectionality appropriate Accuracy, sensitivity, specificity, accessibility affordability key considerations chemosensory tests. Odor taste assessment delivery tools should follow FDA guidelines including performance testing demonstrate reliability detection loss chemosensory function be considered “Generally Recognized Safe” GRAS). Non-responsive Projects do have infrastructure rapidly report study findings impact the DCC. Projects have limited testing capacity, do include FDA-authorized/approved testing strategies present plan incorporate approved testing strategies Review Process Applications be evaluated scientific technical merit an appropriate internal review panel convened NIH staff, accordance the review criteria specified PA-20-135 well these additional review criteria: Urgency significance research: will successful completion the aims contribute or complement public health efforts the control detection SARS-CoV-2 COVID-19) infection related pathogenic processes? Research strategy: the overall strategy, methodology, analyses well-reasoned appropriate accomplish specific aims the project? feasible appropriate the overall research design elements including power calculations) demonstrating effectiveness impact the proposed COVID-19 diagnostic testing? the emergency time frame appropriate feasible support aims goals the study? Investigators: the PD/PIs, collaborators, other researchers well suited appropriate carry the project? Outcomes: outcomes products proposed impact improve acceptability, accessibility, effectiveness COVID-19 testing? Testing: feasible appropriate the plans access FDA-authorized/approved test kits related activities i.e., ability process tests a timely manner return test results quickly possible)?  Data Sharing Plan: the proposed research generate unique resources data may impact public health response medical countermeasure development, does resource sharing plan adequately address rapid dissemination data, results, analyses the broader scientific community, using existing public repositories whenever possible not limited Tribal data sharing policy, a foundation further study? Coordination plans:How feasible appropriate the plans submit data, data collection instruments, outcomes/products the DCC? Pre-Award costs Pre-award costs be incurred January 20, 2020 through public health emergency period prior the date the federal award. Reporting Funds awarded using appropriations provided the “Paycheck Protection Program Health Care Enhancement Act, Public Law 116-139” be issued unique subaccounts the HHS Payment Management System will require separate financial reporting any funds awarded. Application Submission Information Application due date: September 15, 2020 5:00 PM local time applicant organization. Submit applications this initiative response the following funding opportunity announcement FOA) the subsequent reissued equivalent through expiration date this notice: PA-20-135- Emergency Competitive Revision Existing NIH Awards Emergency Supplement - Clinical Trial Optional) Eligibility Active research resource grants, cooperative agreements small business grants SBIR STTRs). NRSA training fellowship grants not eligible apply funding. Product development, validation, scale-up activities supporting commercialization all within scope this NOSI. be eligible a competing revision award under NOSI, parent award which revision application based must an active award including those a no-cost-extension period) managed one the participating institutes centers. Grants currently a no-cost extension eligible apply. instructions the SF424 R&R) Application Guide the parent funding opportunity announcement must followed, the following additions: funding consideration, applicants must include “NOT-OD-20-152” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Applications non-responsive terms this NOSI be be considered. Requests expected to exceed 250,000 total direct costs. Total direct costs requested not exceed direct cost amount the current year’s award. Maximum direct costs exclusive consortium/contractual Facilities Administrative F&A) costs. Requests limited one year support. Regardless the grant mechanism the parent award, Research Strategy section the application limited 6 pages. Where applicable, provide details appropriate biohazard management plans commensurate the level risk https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html). Applications conducting research the SARS-CoV-2 virus specimens possible SARS-CoV-2 infection must address protections against potential biohazards, including details access special facilities, e.g., Biosafety Level 3/4 BSL3/4) laboratories. Potential applicants strongly encouraged contact Program Official listed the Notice Grant Award the parent project discuss responsiveness appropriate mechanism before submission to facilitate efficient processing the request. Inquiries Please direct inquiries one the following contacts: Susan Sullivan, Ph.D. National Institute Deafness Other Communication Disorders NIDCD): 301-451-3841 sullivas@nidcd.nih.gov Amanda Melillo, Ph.D. National Institute Dental Craniofacial Research NIDCR 301-312-9037 amanda.melillo@nih.gov Coryse St. Hillaire-Clarke, Ph.D. National Institute Aging NIA) 301-827-6944 sthillaireclacn@mail.nih.gov Nahida Chakhtoura, Ph.D. Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) 301-435-6872 nahida.chakhtoura@nih.gov Jim Gnadt, Ph.D. National Institute Neurological Disorders Stroke NINDS) 301-496-9964 gnadtjw@ninds.nih.gov Michelle Hamlet National Institute Nursing Research NINR) 301-496-9623 hamletm@mail.nih.gov Rajasri Roy Office Research Women's Health ORWH) 301-451-0993 rajasri.roy@nih.gov

Notice of Intent to Publish a Funding Opportunity Announcement for NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (U54 Clinical Trial Not Allowed)

NOT
Wednesday, July 29, 2020
Monday, November 9, 2020
NOT-RM-20-023

Funding Opportunity Purpose

The purpose of this Notice is to inform the research community that the NIH Common Fund, along with its partner NIH Institutes, Centers, and Offices, is planning to issue a funding opportunity announcement (FOA) to support the NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort. We expect to re-release this funding opportunity for a total of 3 rounds. This Notice is being provided to allow potential applicants sufficient time to develop meaningful plans for robust applications to this opportunity. The FOA is expected to be published in Fall, 2020 with an expected application due date in November 2020. This FOA will utilize the U54 activity code. Details of the planned FOA are provided below. Research Initiative Details The NIH supported biomedical research workforce is more likely to thrive in environments that support equity, diversity, and social justice. The overall program objective of Faculty Institutional Recruitment for Sustainable Transformation (FIRST) is to create cultures of inclusive excellence at NIH-funded institutions by implementing a set of well-integrated, evidence-based strategies and evaluating their impact on prespecified metrics of institutional culture, inclusion, and diversity. Inclusive excellence is a philosophical approach to higher education administration and processes that means attending to both the demographic diversity of faculty/students and the need for developing climates and cultures in institutions so that all have a chance to succeed in STEMM (National Academies of Sciences, Engineering, and Medicine 2019. The Science of Effective Mentorship in STEMM (STEMM stands for Science, Technology, Engineering, Mathematics, and Medicine)). The FIRST Program will provide one funding mechanism with opportunities for Highly Resourced Institutions (HRI) and Limited-Resourced Institutions (LRI) to apply independently or in a partnership arrangement to develop and implement faculty cohort models for the simultaneous hiring of a diverse group of research faculty. LRIs are institutions offering doctorate degrees in the health professions or in a health-related science and have a historical and current commitment to educating underrepresented students, and for institutions that deliver health care services, providing clinical services to medically underserved communities. They must also have received less than $50 million average in annual NIH funds within the three years prior to the time of application (applies Research Centers in Minority Institutions criteria ). Any individual who is competitive for a tenure track faculty position and who has demonstrated a strong commitment to promoting diversity and inclusive excellence is eligible for FIRST faculty positions. Faculty candidates will be required to submit a statement describing their commitment to promoting diversity and inclusive excellence. Institutions will decide how to evaluate this commitment, but some examples include the area of a candidate’s research program, active participation in diversity efforts, mentoring individuals from underrepresented backgrounds, volunteer activities in the community, etc. Selection for the program should be competitive and inclusion in the FIRST cohort will be viewed as a prestigious recognition of outstanding accomplishments both in scientific research and in promoting diversity and inclusive excellence. The program will support activities for faculty to receive multilevel mentoring, sponsorship, professional and research development embedded within institutions that are actively implementing integrated, systems-level approaches for sustainable culture change. FIRST applicant institutions are encouraged to enhance the diversity of the FIRST faculty cohort by including candidates from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences, some of which are described in NOT-OD-20-031, such as racial and ethnic minorities, those from disadvantaged backgrounds, individuals with disabilities, and women at the faculty level. Institutional cohorts may be comprised of small clusters of scientists within several scientific areas, such as neuroscience, cardiovascular disease, cancer, minority health and health disparities, behavioral, social, or other research areas within the NIH mission either at one institution or at partnering institutions. FIRST Cohort programs will operationalize through three cores—Administrative, Faculty Development, and Evaluation cores. The overall goals and specific measurable objectives that the program expects to accomplish are in the areas of: sustainable institutional culture change; promote inclusive excellence by hiring a diverse cohort of new faculty; faculty development, mentoring, sponsorship, and promotion. Each institution will be responsible for evaluating its own FIRST program. The CEC will be responsible for evaluating the attainment of FIRST goals consortium wide.

Pages